Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2022 | Immune dysregulation in myeloma and impact on disease progression

David Avigan • 26 Aug 2022
IMS 2022
Multiple Myeloma

David Avigan, MD, Harvard Medical School, Boston, MA, briefly discusses the importance of investigating immune dysregulation in patients with multiple myeloma, highlighting the role of T-cell exhaustion and how this may impact disease progression. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

More from David Avigan

Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma 2:26
Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
David Avigan • 26 Aug 2022
The role of vaccines in AML 1:26
The role of vaccines in AML
David Avigan • 26 Aug 2022
Vaccines and immunotherapy in hematological malignancies 3:31
Vaccines and immunotherapy in hematological malignancies
David Avigan • 8 Sep 2020
CAR-T: hurdles and ladders 16:02
CAR-T: hurdles and ladders
Adam Cohen et al. • 13 Sep 2019

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals